Amgen Outlines Long-Term Strategy
Amgen today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City.
Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus on innovation, discovery and development of breakthrough molecules to address significant unmet medical needs, and manufacturing of high-quality biologics. Bradway highlighted how certain elements of the company's strategy have evolved:
-- Research and Development (R&D): A more selective approach to R&D, embracing a "pick the winners" strategy with greater focus on human genetics to identify and validate targets, and a strong commitment to return on capital;
-- Commercial: Transformation of the commercial model with an emphasis on expanded access and value to payers, increased presence in key new and emerging markets, investment in new growth opportunities, including biosimilars, and greater product differentiation through drug delivery devices; and
-- Manufacturing: Emphasis on new manufacturing processes and technologies, driving expanded throughput and flexibility and lower capital needs.
"Amgen is in a unique position to capitalize on major advances in drug discovery and biologics manufacturing," said Bradway. "We are making strategic investments to drive long-term growth and deliver for both patients and shareholders." More Strategic Approach to R&D Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, discussed Amgen's new strategic approach to R&D and provided highlights of the company's ongoing clinical programs.
The company's R&D approach will continue to focus on innovations that address significant unmet needs for patients with serious illnesses, but will follow four strategic priorities:
-- Demonstrating the value of our medicines;
-- Following a "biology first" approach;
-- Identifying and validating targets through human genetics; and
-- Driving improvements in operational efficiency.
Amgen will continue to be opportunistic about acquiring external innovation to complement internal capabilities and programs.
"Amgen is uniquely positioned to shape the future of biotechnology," said Harper. "Our new R&D strategy embraces a 'pick the winners' approach, which takes advantage of the knowledge we've gained from decades of experience and our industry-leading position in human genetics that has resulted from our acquisition of deCODE." Harper said Amgen's late-stage pipeline is advancing with data expected from eight pivotal programs by 2016. Highlights include:
-- AMG 145: The AMG 145 Phase 3 program will enroll more than 26,000 patients across seven studies, including the treatment of hyperlipidemia with AMG 145 in: 1,700 patients at risk for cardiovascular disease who are on statin therapy; 300 patients who cannot tolerate statins; 600 patients as monotherapy; and 300 patients with heterozygous familial hypercholesterolemia.
Results from these four Phase 3 trials are expected in 2014. Additionally, a long-term Phase 3 outcomes trial is evaluating treatment with AMG 145 in combination with statins in 22,500 patients at high cardiovascular risk with results expected in 2018.
-- Romosozumab (AMG 785): The romosozumab program will enroll approximately 10,000 postmenopausal osteoporosis patients in two pivotal Phase 3 studies: A pivotal placebo-controlled trial that will evaluate incidence of new vertebral fractures at 12 and 24 months in 6,000 patients; and An active-controlled trial versus alendronate that will evaluate the incidence of clinical fracture and new vertebral fracture at 12 and 24 months in 4,000 patients.
-- Brodalumab (AMG 827): In Phase 3 for psoriasis. Results expected in 2014.
-- AMG 416: In Phase 2 for secondary hyperparathyroidism. Results expected in 2014.
-- Talimogene laherparepvec: In Phase 3 for melanoma. Results expected in 2013.
-- Trebananib (AMG 386): In Phase 3 for ovarian cancer. Results expected beginning in 2013.
-- Blinatumomab (AMG 103): In Phase 2 for acute lymphocytic leukemia.
Results expected in 2014.
-- Rilotumomab (AMG 102): In Phase 3 for gastric cancer. Results expected in 2016.
Harper also discussed AMG 334, a calcitonin gene-related peptide (CGRP) receptor antagonist monoclonal antibody, as an example of Amgen's innovative approach to R&D.
Transforming the Commercial Model to Drive Revenue Growth During the meeting, Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, reviewed how Amgen is transforming its commercial model to build on its existing strengths and to enable new opportunities. He outlined several growth opportunities, including significantly expanding Amgen's geographic footprint, leveraging strong specialty market experience, continuing to build competitive biologic primary care competencies, and creating an integrated commercial model for payers, prescribers and patients.
-- Growth and Differentiation of In-Market Products: Enbrel (etanercept), the leading biologic in value terms within the fast-growing rheumatology and dermatology segments, continues to be the leading choice for new-to-biologic rheumatoid arthritis patients.
Prolia and XGEVA (denosumab) combined delivered $1.2 billion in sales in 2012. This franchise is expected to exceed $3 billion in revenues over time. Growth-phase products Sensipar (cinacalcet), Vectibix (panitumumab), and Nplate (romiplostim) have strong momentum and have opportunities for continued growth.
-- New Product Launches:
Amgen reviewed the commercial opportunities for both AMG 145 and romosozumab.
-- Biosimilars: Amgen outlined plans to launch a portfolio of six new biosimilars beginning in 2017, and noted that biosimilars represent a multi-billion dollar growth opportunity for Amgen.
-- New and Emerging Markets: Amgen expects to deliver over $1 billion in sales in new and emerging markets by 2015 and plans to expand its operating footprint in key markets, including Japan and China.
Currently, the company is exploring a partnership opportunity in Japan that will provide a stand-alone, fully-scaled subsidiary by 2020.
Amgen also expects to launch its first products in the Japanese market by 2016. The company has a multi-pronged strategy for China that includes establishing an R&D presence and local manufacturing when needed, and is exploring partnerships and acquisitions to accelerate its commercial presence. Amgen also expects to launch its first products in the Chinese market by 2015.
Strong Execution Supports Continued Financial Success Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, reviewed Amgen's results over the past 12 months, and the strategic priorities that will allow the company to successfully execute plans for broad-based growth in 2013 and into the future.
For 2013, Amgen now expects to deliver adjusted EPS of $7.05 to $7.35 and an adjusted tax rate of between 12 percent and 13 percent, including the benefit of the Puerto Rico Excise Tax Credit. This update to our guidance is due to federal tax settlements for prior years that resulted in an adjustment to the tax charge for those years that will be recorded in the first quarter. Peacock confirmed that the revenues and capital expenditures guidance for 2013 remains unchanged.
Peacock highlighted strong commercial execution, continued pipeline progress, increased focus on operational excellence and return on investment, recent acquisitions, and capital allocation strategy.
Peacock said Amgen expects to deliver approximately $800 million of operating income benefit in 2014 to shareholders from the transition of the Enbrel profit share to a royalty payment. Shareholders will realize a further increase of approximately 10 percent of Enbrel sales in 2017 as a result of the termination of the royalty payment. In addition, Amgen will reallocate approximately $1 billion in operational efficiencies over the next three years towards strategic initiatives that support the company's growth and competitive position.
Peacock detailed that Amgen has continued to execute on its capital allocation strategy focused on returning, on average, more than 60 percent of adjusted net income to shareholders through dividend growth and share repurchases. Since the April 2011 Business Review, this strategy has led to significant returns to shareholders and an improved return on equity.
A webcast of the Amgen Business Review meeting with presentation slides and video is available through www.amgen.com. The webcast will be archived and available for replay at least 30 days after the event.